Related Experiment Videos
Progress in understanding Friedreich's ataxia using human induced pluripotent stem cells
Anna M Schreiber1, Julia O Misiorek1, Jill S Napierala2
1Department of Molecular Biomedicine, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Expert Opinion on Orphan Drugs
|March 5, 2019
Summary
Induced pluripotent stem cells (iPSCs) are crucial for modeling Friedreich's ataxia (FRDA) by creating patient-specific neuronal and cardiac cells. These models are vital for developing and testing new therapies for FRDA.
Area of Science:
- Neuroscience
- Genetics
- Stem Cell Biology
Background:
- Friedreich's ataxia (FRDA) is a genetic disorder caused by GAA repeat expansion in the frataxin (FXN) gene.
- This expansion leads to reduced frataxin protein, primarily affecting neuronal and cardiac cells.
- Developing effective therapies for FRDA necessitates robust cellular models.
Purpose of the Study:
- To review the use of human induced pluripotent stem cells (iPSCs) for modeling FRDA.
- To highlight the importance of patient-derived and isogenic cell lines in FRDA research.
- To discuss the potential of iPSC-derived models in advancing FRDA therapeutics.
Main Methods:
- Utilizing human induced pluripotent stem cells (iPSCs) for disease modeling.
- Differentiating iPSCs into relevant cell types, including neurons and cardiomyocytes.
- Employing patient-specific and isogenic control cell lines to mitigate biological variability.
Main Results:
- iPSC technology enables the creation of versatile cellular models for FRDA.
- Patient and isogenic iPSC lines are essential for accurate disease modeling and drug screening.
- Differentiated iPSC models recapitulate key aspects of FRDA pathology.
Conclusions:
- iPSC-derived cellular models offer significant advantages for developing novel FRDA therapeutic strategies.
- Rigorous validation of treatments in these models is critical for regulatory approval.
- Advancements in differentiation protocols, particularly for sensory neurons and organoids, will enhance iPSC utility in drug discovery for FRDA.